SK Bioscience Readies $1.3bn IPO Amid Rosy Vaccine Outlook
Expects Continued Rise In COVID-19 Vaccine Demand
Vaccine specialist SK Bioscience is set to launch potentially South Korea’s biggest biopharma IPO next month on the back of a growing premium vaccine business, new opportunities in COVID-19 vaccines and its contract manufacturing operations.
